This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

1Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, Texas. *Corresponding Author: Guillermina Lozano, Department of Genetics, The University of Texas MD Anderson ...

1Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 2Department of Radiation Oncology, Harbin Medical University Cancer Hospital, Harbin, ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

*Corresponding Author: Mara H. Sherman, Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, 1261, New York, NY 10065. E-mail: [email protected] ...

1Department of Population Health Sciences, Weill Cornell Medicine, New York, New York. 2Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York. *Corresponding Author: Kevin ...

According to a newly published article, immune cells with a loss of the Y chromosome (LOY) are less equipped to attack cancer cells than their Y chromosome-containing counterparts (Nature 2025 Jun 4 ...

The FDA today approved Bayer’s darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. The decision was based on the results of the phase III ...

1Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, Florida. 2Immunology, Genome Regulation and Cell Signaling Program, The Wistar Institute, Philadelphia, Pennsylvania. 3Department of ...